
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $5,360.0 million
Deal Type : Collaboration
Argo Announces License and Option Agreements with Novartis for Novel Molecules
Details : An option granted to Novartis to license ex-China rights to two discovery-stage molecules for the treatment of sHTG and mixed dyslipidemia and a right of first negotiation to BW-00112 (ANGPTL3).
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $160.0 million
September 03, 2025
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $5,360.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-20507
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of BW-20507 with PEG-IFNα in Hepatitis B
Details : BW-20507 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 22, 2025
Lead Product(s) : BW-20507
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-40202
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers
Details : BW-40202 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : BW-40202
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-20805
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 in Adult Subjects With Hereditary Angioedema
Details : BW-20805 is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Angioedemas, Hereditary.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : BW-20805
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Patients With Mixed Dyslipidemia
Details : BW-00112 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : BW-00112
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
Shanghai Argo Announces RNAi Licenses and Collaborations with Novartis
Details : Argo has granted Novartis global licenses to develop and commercialize a Phase 1 program, allowing Novartis to select targets and drive discovery and optimization of lead candidates.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $185.0 million
January 07, 2024
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
